LIVE

MLAB

Mesa Laboratories, Inc.

MLAB

NASDAQ·Healthcare·Medical - Equipment & Services·Mkt cap $576.7M

$105.54

▲ +1.10%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$55.45 - $113.99

P/E

164.91

Fwd P/E

8.96

Beta

0.93

Div Yield

0.61%

Avg Vol

186.4K

Shares Out

5.5M

Mkt Cap

$576.7M

Price action

Price chart

Up 3.7% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

5 reasons

  • Specialized expertise and regulatory certifications in mission-critical quality control applications that are difficult to replicate
  • Recurring revenue model through consumables (indicators, reagents, kits) that lock in customer relationships
  • Diversified end-markets reduce dependency on single industry; presence across pharma, medical devices, hospitals, and clinical labs
  • Established distribution networks and customer relationships built over 40+ years of operation
  • High barriers to entry due to regulatory requirements, validation processes, and technical complexity
▼

Bear Case

1 risk

  • Average volatility.

Growth

Stable outlook

Steady revenue growth (11% YoY)

Value

Deep value opportunity - significant discount to Electronics Manufacturing Services peers

Momentum

Strong

+14.6% over 3m

Quality

Excellent

Excellent business quality

Dividend

Modest

0.61% yield

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Aug 4, 2026

“
Q2 26 RECAP

MAY 27, 2026

Reported EPS of $2.76 vs $2.09 consensus (+32.1% surprise). Revenue of $63.7M vs $65.2M expected (-2.3%).

EPS beat +32.1%
Revenue miss

EPS surprise · last 4Q

1 of 1 beats

Q2 26

+32.1%

Next: Aug 4, 2026

Revenue trend · last 8Q

—

—

—

+18%

+5%

+2%

+5%

+4%

Q4 24

Q1 24

Q2 24

Q3 24

Q4 25

Q1 25

Q2 25

Q3 25

$58.9M

$58.2M

$57.8M

$62.8M

$62.1M

$59.5M

$60.7M

$65.1M

Margins · last 8Q

Gross

64.2%

Operating

12.2%

Profit

5.6%

View full earnings history →

Wall Street consensus

1 analyst · 0% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

0%

Hold

1

100%

Sell

0%

Median Price Target

—

Latest: Wells Fargo · $94.00 · Feb 4, 2026

View full analyst page →

vs Industry

How MLAB stacks vs Medical - Equipment & Services

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.